FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2432389462> ?p ?o ?g. }

• W2432389462 endingPage "138" @default.
• W2432389462 startingPage "138" @default.
• W2432389462 abstract "Abstract Background: ABL001 is a potent, specific BCR-ABL inhibitor in development for the treatment of patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. ABL001 binds a pocket on the BCR-ABL kinase domain normally occupied by the myristoylated N terminus of ABL1, which serves an autoregulatory function subsequently lost upon fusion with BCR. ABL001 functionally mimics this autoregulatory role and restores negative regulation of kinase activity. In preclinical studies, ABL001 selectively inhibits the growth of BCR-ABL-positive cells, with activity noted against clinically observed TKI resistance mutations. ABL001 exhibits potent antitumor activity in KCL-22 xenografts, with evidence of complete tumor regression correlating with pSTAT5 inhibition. Animals receiving ABL001 and nilotinib in combination achieved sustained tumor regression without emergence of resistant disease even after treatment discontinuation. Methods: Patients with CML in chronic or accelerated phase with failure of ≥ 2 prior TKIs due to resistance or intolerance were enrolled on this first-in-human, multicenter, open-label phase 1 dose-escalation study (CABL001X2101). Escalating doses of single-agent ABL001 were administered orally on a continuous twice daily (BID) dosing schedule. Treatment continued until disease progression, unacceptable toxicity, consent withdrawal, or death. The primary objective was to estimate the maximum tolerated dose (MTD) of ABL001 administered as a single agent, orally, BID. Secondary objectives included safety, preliminary anti-CML activity, and pharmacokinetics of ABL001. Dose escalation followed a Bayesian logistic regression model based on dose-limiting toxicities (DLTs) occurring in cycle 1. Adverse events (AEs) were graded according to NCI-CTCAE v4.03. Efficacy analysis was based on hematologic, cytogenetic, and molecular assessments. Results: At data cutoff, 35 patients had been treated at the following BID doses: 10 mg (n = 1), 20 mg (n = 5), 40 mg (n = 12), 80 mg (n = 11), 150 mg (n = 6), and MTD has not yet been reached. Median age was 56 years (range, 23-74 years). Most patients (97%) had baseline Eastern Cooperative Oncology Group performance status 0-1. Patients were heavily pretreated; 20 (57%) had received ≥ 3 prior TKIs. In 30 patients, treatment is ongoing at doses 20-150 mg BID, with median duration of exposure of 20.9 weeks (range, 0-49.7 weeks), and 5 patients discontinued (disease progression [n = 1], AEs [n = 3], stem cell transplant [n = 1]). Preliminary data suggests ABL001 pharmacokinetics is dose-proportional with minimal accumulation across dose and time. There were 3 DLTs: 1 grade 3 lipase elevation and 1 grade 2 arthralgia at 40 mg BID and 1 acute coronary syndrome at 150 mg BID. In addition, 3 cases of grade 2 acute pancreatitis occurred in cycle 5 at doses ≥ 80 mg BID. The majority of AEs regardless of study drug relationship were grade 1/2. Most common grade 3/4 AEs were anemia (9%), thrombocytopenia (6%), neutropenia (6%), and lipase increase (6%). No deaths have occurred on study. 20 patients (10-80 mg) on therapy for ≥ 3 months had hematologic, cytogenetic, and molecular assessments. 17 patients were resistant to and 3 were intolerant of prior TKIs. Evidence of single agent activity was noted at doses ≥ 10 mg BID. All patients in complete hematologic (CHR) or complete cytogenetic (CCyR) response or with BCR-ABL ≤ 0.1 % IS at baseline have maintained responses. All 5 patients in hematologic relapse achieved CHR within 3 months. 9 of 11 TKI-resistant patients in cytogenetic relapse (> 65% Ph+ metaphases at baseline) achieved a major cytogenetic response by 3 months, including 6 who achieved CCyR. Of 17 TKI-resistant patients with baseline BCR-ABL > 0.1 % IS, 11 achieved a ≥ 1-log reduction in BCR-ABL % IS and 5 achieved major molecular response by 5 months. Clinical activity was seen across TKI-resistant mutations, including Y253H and V299L. Only 1 patient in accelerated phase has relapsed on study, with relapse due to a mutation in the myristoyl pocket. Conclusion: ABL001 exhibits rapid dose-dependent antitumor activity and appears well tolerated to date in a heavily pretreated subgroup of patients with CML, providing proof of principle of the effectiveness of allosteric inhibition of the BCR-ABL kinase in the treatment of CML. The phase 1 study is ongoing in dose escalation. Disclosures Ottmann: Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Ariad: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Honoraria, Membership on an entity's Board of Directors or advisory committees. DeAngelo:Bristol Myers Squibb: Consultancy; Amgen: Consultancy; Ariad: Consultancy; Celgene: Consultancy; Pfizer: Consultancy; Incyte: Consultancy; Agios: Consultancy; Novartis: Consultancy. Goh:Roche: Honoraria; Janssen: Honoraria, Research Funding; Gilead Sciences: Honoraria; Sanofi: Honoraria; Novartis: Honoraria, Research Funding; Bristol-Myers Squibb: Honoraria; Celgene: Honoraria. Heinrich:Bristol-Myers Squibb: Research Funding; Pfizer: Consultancy, Honoraria, Research Funding; Blueprint Pharmaceuticals: Consultancy; Ariad: Consultancy; Novartis: Consultancy, Honoraria, Patents & Royalties, Research Funding; MolecularMD: Consultancy, Equity Ownership, Research Funding. Hochhaus:ARIAD: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Bristol-Myers Squibb: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding. Hughes:ARIAD: Honoraria, Research Funding; Bristol-Myers Squibb: Honoraria, Research Funding; Novartis: Honoraria, Research Funding. Mahon:ARIAD: Consultancy; Novartis: Consultancy, Honoraria; Pfizer: Consultancy; Bristol-Myers Squibb: Consultancy, Honoraria. Mauro:Novartis Pharmaceutical Corporation: Consultancy, Research Funding; Ariad: Consultancy; Pfizer: Consultancy; Bristol-Myers Squibb: Consultancy. Minami:Novartis: Honoraria, Other: Member of IDMC , Research Funding. Rea:Bristol-Myers Squibb: Honoraria; Pfizer: Honoraria; Ariad: Honoraria; Novartis: Honoraria. Steegmann:Novartis: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; Bristol-Myers Squibb: Honoraria, Research Funding; Ariad: Honoraria, Research Funding. Chatterjee:Novartis Pharmaceuticals: Employment. Iyer:Novartis Pharmaceuticals: Employment, Equity Ownership. Martinez:Novartis Institute for Biomedical Research: Employment. Vanasse:Novartis Pharmaceuticals: Employment, Equity Ownership. Dong-Wook:ll-Yang: Consultancy, Honoraria, Research Funding; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Bristol-Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis Pharmaceuticals: Consultancy, Honoraria, Research Funding, Speakers Bureau." @default.
• W2432389462 created "2016-06-24" @default.
• W2432389462 creator A5008958861 @default.
• W2432389462 creator A5015789771 @default.
• W2432389462 creator A5031805513 @default.
• W2432389462 creator A5033602150 @default.
• W2432389462 creator A5035964802 @default.
• W2432389462 creator A5038000746 @default.
• W2432389462 creator A5040097130 @default.
• W2432389462 creator A5049971021 @default.
• W2432389462 creator A5055797334 @default.
• W2432389462 creator A5060293792 @default.
• W2432389462 creator A5064625563 @default.
• W2432389462 creator A5065774820 @default.
• W2432389462 creator A5075844368 @default.
• W2432389462 creator A5077463490 @default.
• W2432389462 creator A5082924494 @default.
• W2432389462 creator A5089137663 @default.
• W2432389462 creator A5091057405 @default.
• W2432389462 creator A5091315264 @default.
• W2432389462 date "2015-12-03" @default.
• W2432389462 modified "2023-10-16" @default.
• W2432389462 title "ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy" @default.
• W2432389462 doi "https://doi.org/10.1182/blood.v126.23.138.138" @default.
• W2432389462 hasPublicationYear "2015" @default.
• W2432389462 type Work @default.
• W2432389462 sameAs 2432389462 @default.
• W2432389462 citedByCount "23" @default.
• W2432389462 countsByYear W24323894622016 @default.
• W2432389462 countsByYear W24323894622017 @default.
• W2432389462 countsByYear W24323894622018 @default.
• W2432389462 countsByYear W24323894622019 @default.
• W2432389462 countsByYear W24323894622020 @default.
• W2432389462 countsByYear W24323894622021 @default.
• W2432389462 countsByYear W24323894622022 @default.
• W2432389462 countsByYear W24323894622023 @default.
• W2432389462 crossrefType "journal-article" @default.
• W2432389462 hasAuthorship W2432389462A5008958861 @default.
• W2432389462 hasAuthorship W2432389462A5015789771 @default.
• W2432389462 hasAuthorship W2432389462A5031805513 @default.
• W2432389462 hasAuthorship W2432389462A5033602150 @default.
• W2432389462 hasAuthorship W2432389462A5035964802 @default.
• W2432389462 hasAuthorship W2432389462A5038000746 @default.
• W2432389462 hasAuthorship W2432389462A5040097130 @default.
• W2432389462 hasAuthorship W2432389462A5049971021 @default.
• W2432389462 hasAuthorship W2432389462A5055797334 @default.
• W2432389462 hasAuthorship W2432389462A5060293792 @default.
• W2432389462 hasAuthorship W2432389462A5064625563 @default.
• W2432389462 hasAuthorship W2432389462A5065774820 @default.
• W2432389462 hasAuthorship W2432389462A5075844368 @default.
• W2432389462 hasAuthorship W2432389462A5077463490 @default.
• W2432389462 hasAuthorship W2432389462A5082924494 @default.
• W2432389462 hasAuthorship W2432389462A5089137663 @default.
• W2432389462 hasAuthorship W2432389462A5091057405 @default.
• W2432389462 hasAuthorship W2432389462A5091315264 @default.
• W2432389462 hasBestOaLocation W24323894621 @default.
• W2432389462 hasConcept C126322002 @default.
• W2432389462 hasConcept C143998085 @default.
• W2432389462 hasConcept C197934379 @default.
• W2432389462 hasConcept C2776960273 @default.
• W2432389462 hasConcept C2777413986 @default.
• W2432389462 hasConcept C2777583451 @default.
• W2432389462 hasConcept C2778461978 @default.
• W2432389462 hasConcept C2778715236 @default.
• W2432389462 hasConcept C2778729363 @default.
• W2432389462 hasConcept C29730261 @default.
• W2432389462 hasConcept C71924100 @default.
• W2432389462 hasConcept C98274493 @default.
• W2432389462 hasConceptScore W2432389462C126322002 @default.
• W2432389462 hasConceptScore W2432389462C143998085 @default.
• W2432389462 hasConceptScore W2432389462C197934379 @default.
• W2432389462 hasConceptScore W2432389462C2776960273 @default.
• W2432389462 hasConceptScore W2432389462C2777413986 @default.
• W2432389462 hasConceptScore W2432389462C2777583451 @default.
• W2432389462 hasConceptScore W2432389462C2778461978 @default.
• W2432389462 hasConceptScore W2432389462C2778715236 @default.
• W2432389462 hasConceptScore W2432389462C2778729363 @default.
• W2432389462 hasConceptScore W2432389462C29730261 @default.
• W2432389462 hasConceptScore W2432389462C71924100 @default.
• W2432389462 hasConceptScore W2432389462C98274493 @default.
• W2432389462 hasIssue "23" @default.
• W2432389462 hasLocation W24323894621 @default.
• W2432389462 hasOpenAccess W2432389462 @default.
• W2432389462 hasPrimaryLocation W24323894621 @default.
• W2432389462 hasRelatedWork W1541524216 @default.
• W2432389462 hasRelatedWork W1973550048 @default.
• W2432389462 hasRelatedWork W2093322643 @default.
• W2432389462 hasRelatedWork W2246670699 @default.
• W2432389462 hasRelatedWork W2413268903 @default.
• W2432389462 hasRelatedWork W2417816422 @default.
• W2432389462 hasRelatedWork W2576284040 @default.
• W2432389462 hasRelatedWork W2596106165 @default.
• W2432389462 hasRelatedWork W3202998076 @default.
• W2432389462 hasRelatedWork W4362507290 @default.
• W2432389462 hasVolume "126" @default.
• W2432389462 isParatext "false" @default.
• W2432389462 isRetracted "false" @default.
• W2432389462 magId "2432389462" @default.

• next